Literature DB >> 22484725

The mystery of angiographically silent macular oedema due to taxanes.

Tatiana I Kuznetcova1, Petr Cech, Carl P Herbort.   

Abstract

Taxanes are widely used anticancer agents, produced from the plants of the genus Taxus (yews). One of the rare side-effects caused by taxanes is a bilateral cystoid macular oedema (CMO). The particularity of this type of CMO is that it is angiographically silent showing no leakage or pooling on fluorescein angiography (FA). To date, the mechanism of this oedema has not been clearly understood and existing theories do not explain this phenomenon very well. Our aim was to report a case of paclitaxel-induced CMO and put forward a putative explanation for this occurrence. A 64-year-old woman presented with a 7-month history of progressively decreasing bilateral visual acuity with an apparently normal fundus. At entry her best-corrected visual acuity (BCVA) was 0.4 for far and near OD and 0.5 for far and near OS. Optical coherence tomography (OCT) revealed a CMO with a central thickness of 561 μm OD and 488 μm OS; there were no signs of intraocular inflammation. FA showed no capillary leakage and quasi absent late hyperfluorescence OU. Indocyanine green angiography was within normal limits. Classical CMO treatment was ineffective and only discontinuation of paclitaxel resulted in recovery of a normal macular structure after 4 weeks with an increase of BCVA to 0.9 OD and 1.0 OS. In order to understand the properties of taxane drug-induced cystoid macular oedema (TDICMO) we compared the spectral OCT findings of our case to an inflammation-induced CMO of equal thickness and to a case of multifocal choroiditis. The plane of separation of TDICMO was above the external limiting membrane in both cases. In contrast to inflammation-induced CMO where the four external bands were well identified, there was attenuation of these bands in TDICMO but no disruption of the layers as seen in multifocal choroiditis, indicating that the fluid in TDICMO had a high viscosity producing a shadow underneath. TDICMO most probably originates from retinal pigment epithelium dysfunction by their effect on microtubule functions and not from vascular leakage. The content of the CMO seems to be made up of viscous fluid. As the origin of the CMO is not inflammatory, classical CMO treatments have no effect and only discontinuation of the taxane drug allows reversal of the CMO.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484725     DOI: 10.1007/s10792-012-9558-9

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  13 in total

Review 1.  Compare and contrast actin filaments and microtubules.

Authors:  T J Mitchison
Journal:  Mol Biol Cell       Date:  1992-12       Impact factor: 4.138

2.  The pathophysiological mechanism of fluid retention in advanced cancer patients treated with docetaxel, but not receiving corticosteroid comedication.

Authors:  A Béhar; E Pujade-Lauraine; A Maurel; M D Brun; F F Chauvin; F Feuilhade de Chauvin; D Oulid-Aissa; D Hille
Journal:  Br J Clin Pharmacol       Date:  1997-06       Impact factor: 4.335

3.  Paclitaxel maculopathy.

Authors:  Mandar M Joshi; Bruce R Garretson
Journal:  Arch Ophthalmol       Date:  2007-05

Review 4.  Mechanisms of fluid accumulation in retinal edema.

Authors:  M F Marmor
Journal:  Doc Ophthalmol       Date:  1999       Impact factor: 2.379

5.  Optical coherence tomography findings in niacin maculopathy.

Authors:  Hatem Marwan Dajani; Andreas Katsuya Lauer
Journal:  Can J Ophthalmol       Date:  2006-04       Impact factor: 1.882

Review 6.  Pathomechanisms of cystoid macular edema.

Authors:  Andreas Bringmann; Andreas Reichenbach; Peter Wiedemann
Journal:  Ophthalmic Res       Date:  2004 Sep-Oct       Impact factor: 2.892

Review 7.  Risks and benefits of taxanes in breast and ovarian cancer.

Authors:  L B Michaud; V Valero; G Hortobagyi
Journal:  Drug Saf       Date:  2000-11       Impact factor: 5.606

8.  Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome.

Authors:  David G Telander; David Sarraf
Journal:  Semin Ophthalmol       Date:  2007 Jul-Sep       Impact factor: 1.975

9.  Cystic maculopathy with normal capillary permeability secondary to docetaxel.

Authors:  Bruce A Teitelbaum; David J Tresley
Journal:  Optom Vis Sci       Date:  2003-04       Impact factor: 1.973

10.  Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment.

Authors:  K A Semb; S Aamdal; P Oian
Journal:  J Clin Oncol       Date:  1998-10       Impact factor: 44.544

View more
  16 in total

1.  Indocyanine green angiography findings of cystoid macular edema secondary to paclitaxel therapy.

Authors:  Nanami Nomi; Manami Ota; Miho Fukumura; Yoshihisa Nuno; Makoto Hatano; Makiko Wakuta; Ryoji Yanai; Kazuhiro Kimura
Journal:  Jpn J Ophthalmol       Date:  2017-12-21       Impact factor: 2.447

Review 2.  Cystoid macular oedema without leakage in fluorescein angiography: a literature review.

Authors:  Masood Naseripour; Sara Hemmati; Samira Chaibakhsh; Arzhang Gordiz; Leila Miri; Fatemeh Abdi
Journal:  Eye (Lond)       Date:  2022-09-10       Impact factor: 4.456

3.  Single-eye trial of a topical carbonic anhydrase inhibitor versus intravitreal bevacizumab for the treatment of taxane drug-induced cystoid macula oedema.

Authors:  Mark M Hassall; Nicholas Howard Andrew
Journal:  BMJ Case Rep       Date:  2016-04-19

Review 4.  Drug-induced macular edema.

Authors:  Olga E Makri; Ilias Georgalas; Constantine D Georgakopoulos
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

5.  Bilateral cystoid macular edema following docetaxel chemotherapy in a patient with retinitis pigmentosa: a case report.

Authors:  Anna Enzsoly; Kinga Kammerer; Janos Nemeth; Miklos Schneider
Journal:  BMC Ophthalmol       Date:  2015-03-29       Impact factor: 2.209

6.  Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review.

Authors:  Ying Li; Yanping Li; Junyu Li; Guoliang Pi; Wenyong Tan
Journal:  Onco Targets Ther       Date:  2014-07-31       Impact factor: 4.147

7.  Docetaxel Retinopathy: A Case Report.

Authors:  Sylvia Nghiem-Buffet; Salomon Yves Cohen; Audrey Giocanti-Auregan
Journal:  Case Rep Ophthalmol       Date:  2017-01-17

8.  Impaired retinal pigment epithelium in paclitaxel-induced macular edema: A case report.

Authors:  Chia-Hsin Shih; Yuan-Chieh Lee
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

9.  Sub-Tenon Injections of Triamcinolone Acetonide Had Limited Effect on Cystoid Macular Edema Secondary to Nanoparticle Albumin-Bound-Paclitaxel (Abraxane).

Authors:  Naoki Matsuoka; Hiruma Hasebe; Tetsuji Mayama; Takeo Fukuchi
Journal:  Case Rep Ophthalmol Med       Date:  2015-08-23

10.  Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review.

Authors:  Takamichi Yokoe; Ippei Fukada; Kokoro Kobayashi; Tomoko Shibayama; Yumi Miyagi; Atsushi Yoshida; Takuji Iwase; Shinji Ohno; Yoshinori Ito
Journal:  Case Rep Oncol       Date:  2017-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.